Invenomic Capital Administration has utterly exited Haemonetics Company (HAE 0.61%)beforehand bought 498,317 shares price $24.29 million, in response to an SEC submitting dated February 17, 2026.
what occurred
Invenomic Capital Administration bought all 498,317 shares of Haemonetics Company, in response to an SEC submitting dated February 17, 2026. Web place change through the quarter was $24.29 million.
What else you must know
Fund withdrawal from Haemonetics Company lowered the place from 1.2% of 13F AUM final quarter to zero post-filing. Prime holdings after submitting: NASDAQ: VTRS: $69.64 million (3.4% of AUM)NYSE: GPN: $61.73 million (3.0% of AUM)NASDAQ: XRAY: $58.66 million (2.8% of AUM)NASDAQ: AKAM: $58.59 million (2.8% of AUM)NYSE: EGO: $53.75 million (2.6% of AUM) As of Friday, Haemonetics Company inventory was priced at $58.58, down 9% over the previous 12 months and properly under the S&P 500’s acquire of about 16% over the identical interval.
Firm Profile
Firm snapshot
Haemonetics supplies automated plasma assortment units, blood part assortment techniques, hemostasis analyzers, and built-in software program options for blood administration and transfusion. The corporate generates income by promoting medical units, associated disposable merchandise, and its proprietary software program platform to healthcare suppliers and blood facilities. We serve plasma facilities, hospitals, and blood banks, focusing on healthcare organizations that require superior blood administration and transfusion options.
Haemonetics Company is a number one supplier of medical units and software program for blood and plasma administration. The corporate’s technique is concentrated on offering built-in options that enhance the effectivity and security of blood assortment and transfusion processes. With its numerous portfolio and deal with innovation, the corporate has established itself as a key accomplice for healthcare organizations in search of superior blood administration know-how.
What this deal means for traders
Typically, particularly throughout nice rallies, tough stretches can pressure troublesome selections, and that appears to be the case right here. Haemonetics’ inventory worth soared practically 70% within the final quarter alone after the corporate reported better-than-expected third-quarter outcomes. Invenomic seems to have chosen to money out its earnings after a interval of poor efficiency, which looks as if a sensible transfer contemplating the corporate has since written off a lot of that revenue and is down 27% this 12 months.
To be clear, hemonetics doesn’t essentially look like damaged. It is simply dealing with some stress. Final quarter’s gross sales decreased about 3% to roughly $339 million, regardless of continued progress in sure segments reminiscent of plasma and blood administration. The story has grow to be much more advanced, with divestitures, modifications in product combine, and uneven efficiency throughout enterprise traces disrupting what was as soon as a less complicated progress story.
On the similar time, profitability has really elevated. Gross revenue margin expanded to just about 60%, and working earnings additionally elevated. This reveals that the corporate’s effectivity is growing regardless of slowing gross sales momentum. That stress might be the primary cause for leaving. That is not a pure progress play, however it’s additionally not a secure formulation instrument.
